{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:28:55Z","timestamp":1790483335995,"version":"4.1.0"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,10,8]],"date-time":"2011-10-08T00:00:00Z","timestamp":1318032000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2011,11]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Patients with common variable immunodeficiency (CVID) are at high risk of developing immune thrombocytopenia (ITP) and\/or autoimmune haemolytic anaemia (AHA). Given their underlying immunodeficiency, immunosuppressive treatment of these manifestations may increase the risk of infection. To assess efficacy and safety of rituximab in patients with CVID\u2010associated ITP\/AHA, a multicentre retrospective study was performed. Thirty\u2010three patients, 29 adults and four children, were included. Patients received an average of 2\u00b76 treatments prior to rituximab including steroids, intravenous immunoglobulin and splenectomy (21%). The median ITP\/AHA duration at time of first rituximab administration was 12\u2003months [range 1\u2013324] and the indication for using rituximab was ITP (22 cases), AHA (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u20035) or both (\n                    <jats:italic>n<\/jats:italic>\n                    \u2003=\u20037); 1 patient was treated sequentially for ITP and then AHA. The overall initial response rate to rituximab was 85% including 74% complete responses. After a mean follow\u2010up of 39\u2003\u00b1\u200330\u2003months after rituximab first administration, 10 of the initial responders relapsed and re\u2010treatment with rituximab was successful in 7\/9. Severe infections occurred after rituximab in eight adults (24%), four of whom were not on immunoglobulin replacement therapy. In conclusion, rituximab appears to be highly effective and relatively safe for the management of CVID\u2010associated severe immune cytopenias.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2141.2011.08880.x","type":"journal-article","created":{"date-parts":[[2011,10,14]],"date-time":"2011-10-14T07:45:43Z","timestamp":1318578343000},"page":"498-508","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Efficacy and safety of rituximab in common variable immunodeficiency\u2010associated immune cytopenias: a retrospective multicentre study on 33 patients"],"prefix":"10.1111","volume":"155","author":[{"given":"Delphine","family":"Gobert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Bussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Cunningham\u2010Rundles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Galicier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Dechartres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Berezne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Bonnotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"DeRevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Auzary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Jaussaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Larroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"LeQuellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Ruivard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Seve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar","family":"Smail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Fran\u00e7ois","family":"Viallard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Godeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,10,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-1-200701020-00006"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2010.10.002"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.9.1884.1884"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21341"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11181"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1361.111"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-124545"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4799"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04889.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1054\/blre.2001.0185"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1006\/clim.1999.4725"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri1838"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2006.041426"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07054.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-131029"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06616.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2729"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000133624.65946.40"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-215368"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1086\/587669"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e31817a90ba"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.1.58"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22046"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-118-9-199305010-00011"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-068999"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026416017763"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:19:2:157"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2008.05.011"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20072"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2005.04.006"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-229815"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2011.08880.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2011.08880.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T13:59:31Z","timestamp":1697378371000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2011.08880.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["10.1111\/j.1365-2141.2011.08880.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2011.08880.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,8]]},"assertion":[{"value":"2011-10-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}